[Use of fish oil lipid emulsions in hospitalized patients under 18 years old with abnormal results in liver tests associated with total parental nutrition].

Autor:	Giraldo Villa A; Nutricionista clínica. Magíster en epidemiología. Grupo de Soporte Nutricional Pediátrico. Hospital Pablo Tobón Uribe. Colombia. agiraldov85@yahoo.com., Henao Roldan C; Nutricionista clínica. Magíster en nutrición infantil. Grupo de Soporte Nutricional Pediátrico. Hospital Pablo Tobón Uribe. Colombia., García Loboguerrero F; Pediatra subespecialista en cuidado intensivo. Grupo de Soporte Nutricional Pediátrico. Hospital Pablo Tobón Uribe. Colombia., Martínez Volkmar MI; Enfermera especialista en cuidado al niño en estado crítico de salud. Grupo de Soporte Nutricional Pediátrico. Hospital Pablo Tobón Uribe. Colombia., Contreras Ramírez MM; Pediatra Gastroenteróloga. Grupo de Soporte Nutricional Pediátrico. Hospital Pablo Tobón Uribe. Colombia., Ruiz Navas P; Pediatra Gastroenteróloga y nutrióloga. Grupo de Soporte Nutricional Pediátrico. Hospital Pablo Tobón Uribe. Colombia.
Jazyk:	Spanish; Castilian
Zdroj:	Nutricion hospitalaria [Nutr Hosp] 2014 Apr 01; Vol. 29 (4), pp. 844-51. Date of Electronic Publication: 2014 Apr 01.
DOI:	10.3305/nh.2014.29.4.7209
Abstrakt:	Introduction: Prolonged Total Parental Nutrition (TPN) is associated with life-threatening complications in the pediatric population, being cholestasis one of the most important ones. The source of fatty acids, the amount of phytosterols and the dose of lipids in the nutritional support, have been linked to the development of this complication. Purpose: To describe the behavior of liver function tests in pediatric patients with TPN where lipid based omega 3 fatty acids (OmegavenR) were used. Methods: A retrospective research was made in a population of children under 18 years old where omega 3 fatty acids were used for a minimum of 8 days. Patients were initially classified into two groups: cholestasis and abnormal liver tests. Levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TB), direct bilirubin (DB) gamma glutamyl transferase (GGT) and alkaline phosphatase (AP) before and after treatment with OmegavenR was evaluated. Results: 33 patients met the inclusion criteria. At the end of treatment with OmegavenR, 82.4% of patients who initially presented cholestasis showed resolution or improvement. The group of patients with abnormal liver tests 18.8% progressed to cholestasis. Conclusions: Our study suggests that the use of OmegavenR in pediatric patients with TPN and DB ≥ 2 mg/dL, seem to reverse or improve cholestasis while in patients with abnormal liver tests we still don't have clear effect. (Copyright AULA MEDICA EDICIONES 2014. Published by AULA MEDICA. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu